Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
5
A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring
Award last edited on: 6/11/2020
Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$1,860,562
Award Phase
2
Solicitation Topic Code
359
Principal Investigator
Annette Marleau
Company Information
Aethlon Medical Inc
(
AKA
: Bishop Equities Inc)
11555 Sorrento Valley Road Suite 203
San Diego, CA 92121
(619) 941-0360
info@aethlonmedical.com
www.aethlonmedical.com
Location:
Multiple
Congr. District:
50
County:
San Diego
Phase I
Contract Number:
75N91019C00042-0-9999-1
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2019
Phase I Amount
$1
Direct to Phase II
Phase II
Contract Number:
75N91019C00042
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
2019
Phase II Amount
$1,860,561
The proposed work aims to develop a pre commercial prototype of an exosome isolation device to be used in clinical diagnostic laboratories. We will advance the device to facilitate exosome isolation for downstream liquid biopsy tests requiring analysis of proteinDNA or microRNA which rely upon acquisition of intact and pure exosomes. The device strategy will be designed to isolate total exosomes and then to separate discrete populations of tumor derived exosomes TEX and non malignant exosomes non TEX. The device strategy will be advanced for melanoma exosome isolation in the proposed experiments but is expected to be applicable for other cancers. To achieve this study s objectives we will develop and optimize a filtration system incorporating the GNA Hemopurifier for isolation of total exosomes from biofluids Specific Aim. The capabilities of the GNA Hemopurifier for isolating melanoma TEX and non TEX from diverse biofluids will be characterized by evaluating exosome depletion performance Specific Aim. We will then construct a novel device the CSPG cartridge for the isolation of TEX from total exosomes followed by testing the final workflow from the starting biofluid sample to the final TEX isolation Specific Aim. Successful completion of this project will produce an exosome isolation system that will be applicable for high throughput exosome isolation and for TEX and non TEX separation from diverse biofluids of varying complexity in a clinical care setting in oncology
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.